Private label buyers often assume a compliant EU pet product launch takes six months or more, and plan their range reviews accordingly. This case study describes a 90-day path: a European retail group's own-brand plant-based deodorant spray moved from brief to shelf with tight scoping, fast sampling, documentation produced in parallel with development, and coordinated production. The milestones below are anonymised and specific to one project rather than a guarantee. What transfers to other projects is the sequencing, and the three decisions that made the timeline possible.
The Brief and the Three Constraints
The buyer was a mid-sized European retail group with an established pet aisle and a visible gap: no own-brand deodorant in the clean-label segment, where two national brands were taking share at a premium. The brief asked for a plant-based pet deodorant spray, fragrance-free positioning, a price point that undercut the brands without reading as cheap, and packaging that would sit comfortably beside the category leaders on a four-facet shelf.
Three constraints framed everything that followed. First, a 90-day target from brief approval to first delivery, driven by a category review date the retailer could not move. Second, full EU label compliance for the group's existing responsible person arrangement. Third, private-label exclusivity on the formula for the first twelve months. Each constraint eliminated a class of supplier, and together they defined the project more usefully than the product description did.
Why 90 Days Was Possible: Parallel Workstreams
The timeline was not achieved by compressing any single step. It came from running steps that are normally sequential at the same time. Sampling, documentation and artwork review were opened on the same day, with the artwork built against a provisional formula specification that changed only in fragrance level and pH during the revision cycles. In a conventional sequence, artwork waits for the final formula, which waits for stability, which waits for the sample sign-off; that chain alone consumes ten to twelve weeks in most projects.
The constraint is honest disclosure. Parallel work only functions when the buyer accepts that artwork is provisional until the specification freezes, and when the manufacturer flags any change that would invalidate a document already issued. In this project the formula was frozen at day 38, which left enough room for stability at accelerated conditions to start before the artwork went to print and for the batch record to be written against a settled specification.
| Workstream | Typical sequential plan | This project | What made the difference |
|---|---|---|---|
| Brief to approved prototype | 4–6 weeks | Day 1 to day 31 | Started from a validated catalogue base; two revision cycles only |
| Formula freeze | Week 8–10 | Day 38 | Revision scope limited to fragrance level and pH |
| Documentation pack | Weeks 9–16 | Issued from day 12, completed day 45 | Drafted against the base formula and updated as the spec firmed |
| Artwork and label review | Weeks 12–18 | Day 20 to day 52 | Provisional copy reviewed in parallel with sampling |
| Production | Week 18–22 | Day 58 to day 76 | Single private-label run booked before sample approval, on a narrow window |
| QC release and delivery | Week 23–26 | Day 79 to day 88 | COA and retained samples prepared in advance of fill |
Source: anonymised project record from a European private label deodorant launch supported by Puyan; day counts cover one project and are not a standard lead time.
Formula Strategy: Modify a Validated Base
The decision that bought the most time was to start from an existing plant-based deodorant platform rather than open a custom development project. The adjustments were real but contained: surfactant ratio tuned for a lighter residue on coat, fragrance removed entirely rather than swapped for a milder one, pH shifted to support the preservation system at the lower fragrance load, and the fill volume set at 200 ml to hit the target shelf price with a retail-ready carton.
Two revision cycles followed. The first corrected a faint carrier odour that read as “chemical” to the buyer's panel; the second adjusted pH by a few tenths to improve mildness feedback without compromising the challenge test result. Sample turnaround held at 7–10 business days per cycle, which is the practical reason a 90-day window is realistic at all: at three weeks per round, the same two revisions would have consumed a third of the schedule. The plant-based formulation guide covers the ingredient architecture behind a base of this kind, and the plant-based deodorant platform sets out the pack formats available without new tooling.
Documentation Delivered in Parallel
Documentation is where private label launches usually lose weeks, because it is treated as an output of production rather than a workstream of its own. Here the supplier issued the safety data sheet and the base specification on day 12 against the catalogue formula, then amended rather than reissued as the specification firmed. Ingredient declarations, allergen declarations and CLP classification support followed the same pattern, with each version dated and version-controlled so the retailer's responsible person could review a live document rather than wait for a final pack.
Two compliance details shaped the label. The fragrance-free claim had to be verified against the final ingredient list rather than the marketing brief, which is why the fragrance removal was confirmed in writing before artwork was approved. And because the EU fragrance allergen rules in Regulation (EC) No 1223/2009 were amended in 2023 with a phased transition, the label was checked against the version that would apply at the planned on-shelf date rather than the version in force at brief. Our fragrance claims and allergen labelling note sets out the check sequence.
Label and Claim Review Before Artwork Sign-Off
The artwork went through two review rounds, both attended by the retailer's own regulatory contact. The disputed points were predictable: whether “plant-based” needed a quantified percentage, whether “fragrance-free” could sit next to a botanical ingredient name, and how much of the mechanism story could appear on the front panel without implying a biocidal effect. The resolution in each case was to keep the front panel modest and move explanation to the back and the leaflet, which is also where the usage instructions belonged.
That choice protected the schedule. A claim removed at review stage costs an hour; a claim removed after print costs a reprint and a shelf date. The supplier's contribution was to bring a pre-reviewed claim set to the first meeting rather than an open question, so the retailer was choosing between defensible options instead of commissioning new substantiation.
Production, QC and Batch Release
The order was a single private-label run at the platform's standard 1,000-unit-per-SKU minimum for the modified formula, which allowed a dedicated batch with no shared-line scheduling risk. Booking the production window before sample approval was the calculated risk in the project: if the prototype had failed at day 31, the slot would have moved. In practice the two revision cycles closed inside the window, and the batch was filled on day 58 against the frozen specification.
Batch release included a certificate of analysis with narrow specifications, challenge test results for the finished formula, retained samples from the first and last fill, and traceability records from raw-material lot to finished carton. Those four items were the core of the retailer's supplier audit, and having them prepared before the fill rather than after it removed the usual two-week lag between production and permission to ship.
One further control mattered more than expected: a written change rule. Between formula freeze and fill, only three changes were permitted without reopening documentation — fragrance level within a stated range, pH within a stated band, and pack copy corrections that did not alter a claim. Anything outside those limits triggered a documented review. That rule is what stops a live project from drifting into a late reformulation, which is the single most common reason a compliant launch slips past its review date.
The Launch Map: What to Ask For Before Signing
The transferable artefact from this project is a launch map — a dated list of milestones, owners and documents that both parties sign before the purchase order. It converts a conversation about speed into a schedule with named dependencies, and it makes the risk of any late change visible to the buyer rather than absorbed quietly by the supplier. Ask for it in writing, and ask which milestones can move without moving the delivery date.
The map should also state what is not included. Custom fragrance development, organic certification, market-specific registrations and additional language versions all sit outside a 90-day window built on a validated base, and each should appear as a separate line with its own estimate. Our ODM kickoff questions list is a practical companion, and if you are mapping a launch against a fixed review date, send us the date and the brief and we will return a schedule with the dependencies marked.
| Milestone | Target day | Document handed over | Owner |
|---|---|---|---|
| Brief sign-off and base selection | Day 1 | Signed specification brief | Buyer and manufacturer |
| First sample delivery | Day 12 | Sample report, safety data sheet | Manufacturer |
| Formula freeze | Day 38 | Frozen specification and costing | Both parties |
| Documentation pack complete | Day 45 | Ingredient and allergen declarations, CLP support | Manufacturer |
| Artwork approval | Day 52 | Approved print-ready label and leaflet | Buyer |
| Production window | Day 58–76 | Batch record, in-process checks | Manufacturer |
| QC release and delivery | Day 79–88 | COA, retained samples, traceability file | Manufacturer |
Source: anonymised project record; day counts are project-specific and exclude buyer-side decision time beyond the agreed review windows.
Frequently Asked Questions
Is a 90-day EU private label launch realistic for every product?
No. It works when the product can be built from a validated base with limited adjustments, when documentation is opened on day one, and when the buyer can review artwork and copy inside fixed windows. Full custom development, novel packaging tooling, organic certification or a new market registration will not fit in 90 days. Treat the number as a property of a well-scoped project on an existing platform, not as a promise a supplier can make about any brief.
What does EU compliance actually require for a pet deodorant spray?
A pet deodorant with no biocidal or medicinal claim is generally handled as a general consumer product under the General Product Safety Regulation, with CLP classification duties where the mixture is hazardous, and a safety data sheet for the supply chain. The retailer's responsible person arrangement then drives the technical file. If the copy claims to kill or eliminate micro-organisms, the Biocidal Products Regulation comes into scope and the timeline changes completely, so claim wording is a scheduling decision as much as a legal one.
Why start from a catalogue formula instead of a custom one?
Because sampling, stability and documentation can then begin from known data rather than from zero. A catalogue base arrives with a history: preservation results, stability behaviour, ingredient declarations and a costing structure. Adjustments within defined limits can be documented as a variant rather than a new development, which is what makes a two-revision cycle sufficient. Full custom work is still available, but it belongs in a longer plan with its own milestones and cost.
How much buyer-side decision time is included in the 90 days?
In this project, the buyer committed to two named review windows of five working days each for samples and artwork, and honoured both. That commitment matters as much as the manufacturer's schedule: three weeks of silence on a sample approval removes the entire advantage gained by parallel documentation. When planning, write the buyer's review windows into the launch map with dates, and agree in advance who can approve if the named contact is unavailable.
Does a fragrance-free claim need extra substantiation?
It needs verification, which is different and simpler. The claim must be true of the final formula, so confirm in writing that no fragrance is added and that no fragrance allergen appears in the ingredient list. If a botanical extract carries a scent of its own, say so in the supporting copy rather than implying the product has no odour at all. Where a market applies the EU fragrance allergen labelling rules, check the label against the version in force at your on-shelf date.
What MOQ applied to this project and would it have been lower?
The run was placed at the platform's standard minimum of 1,000 units per SKU, which for this assortment was a single facing in roughly 150 stores. Below that level, changeover and documentation costs dominate the unit price and a dedicated private-label batch is no longer economic. If a launch needs a smaller test quantity, the practical route is a stock-pack trial rather than a below-minimum private-label run, followed by the full run once sell-through is proven.
Conclusion
A 90-day private label deodorant launch is achievable, but it is a scheduling achievement rather than a shortcut. It depends on a validated base that can absorb small changes, documentation opened before the formula is final, and a buyer who commits to fixed review windows in writing. The project above shipped on time because nothing in the compliance chain was deferred in order to protect the date. Speed here was the product of sequencing rather than of skipping steps, and that distinction is what makes the timeline repeatable on a second SKU. Treat the launch map as the deliverable you negotiate, ask what sits outside the window, and the schedule stops being an optimistic promise and becomes a plan you can staff against.
See how our Plant-Based Deodorant Spray platform supports private label launch timelines.
